You are here

INVOKANA®: An SGLT2 inhibitor that removes glucose from the body1

Mechanism of action

 

 

Glucose reabsorption

  • The capacity for reabsorption of glucose is increased in patients with type 2 diabetes, contributing to hyperglycemia2

INVOKANA® removes glucose by1:

  • Reducing glucose reabsorption, increasing urinary glucose excretion
  • INVOKANA® results in the excretion of approximately 100 grams of glucose per day1

See RESOURCES

See the results of INVOKANA® AS MONOTHERAPY, VS JANUVIA®VS GLIMEPIRIDE, in PATIENTS WITH RENAL IMPAIRMENT, and in OLDER PATIENTS.

References: 1. INVOKANA® [prescribing information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Gerich JE. Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med. 2010;27(2):136-142.